InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a note issued to investors on Monday. The firm set a "sell" rating on the stock.

InspireMD Stock Performance

NYSE:NSPR traded up $0.03 during mid-day trading on Monday, reaching $2.32. The stock had a trading volume of 19,013 shares, compared to its average volume of 37,245. The firm has a 50 day moving average price of $2.55 and a two-hundred day moving average price of $2.78. The stock has a market capitalization of $54.43 million, a P/E ratio of -2.15 and a beta of 0.84. InspireMD has a one year low of $0.96 and a one year high of $3.85.

InspireMD (NYSE:NSPR - Get Free Report) last released its earnings results on Wednesday, March 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. The company had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same quarter in the previous year, the company posted ($0.60) EPS. Research analysts forecast that InspireMD will post -0.61 earnings per share for the current year.

Hedge Funds Weigh In On InspireMD

A number of large investors have recently bought and sold shares of NSPR. Renaissance Technologies LLC purchased a new position in InspireMD in the 2nd quarter worth approximately $36,000. Marshall Wace LLP purchased a new position in InspireMD in the 2nd quarter worth approximately $4,670,000. Avestar Capital LLC purchased a new position in shares of InspireMD during the third quarter valued at approximately $65,000. McKinley Carter Wealth Services Inc. purchased a new position in shares of InspireMD during the fourth quarter valued at approximately $28,000. Finally, Northern Trust Corp purchased a new position in shares of InspireMD during the fourth quarter valued at approximately $80,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.